This article looks at the 13 Best German Stocks to Invest in Now.
European shares declined on Friday amid losses in bank and mining-related stocks, as investors shifted their focus to the July 9 deadline for trading partners to reach a deal with the United States.
The pan-European STOXX 600 index was down 0.5%, while other regional indexes also dipped, including Germany’s DAX (-0.60%).
However, on a year-to-date basis, the DAX index has gained 19.48%, comfortably outperforming its US counterparts, driven by a robust show by the country’s defense stocks, as European governments unlocked billions to supercharge their militaries.
On June 24, the German cabinet approved a draft budget for 2025 and a budget framework for the following year, which includes heavy investments to stimulate economic growth and further increase the country’s defense spending.
Finance Minister Lars Klingbeil stated the following on the draft budget:
“With this budget and the 500-billion-euro investment fund, we are setting in motion what we need now to ensure new economic strength, make our country modern and future-proof and to enable safe living in Germany in the future as well.”
With that said, let’s now head over to the list of the 13 best German stocks to invest in.
A financial trader on the floor of the Stock Exchange, intently watching the markets.
Methodology
For this article, we identified German stocks listed on American exchanges and ranked them in ascending order of the number of hedge fund investors having a stake in them, based on Insider Monkey’s database of over 1,000 prominent hedge funds as of Q1 2025. In cases where two or more stocks were tied on hedge fund sentiment, we used market cap as a tiebreaker between them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best German Stocks to Invest in Now:
13. Anbio Biotechnology (NASDAQ:NNNN)
Number of Hedge Fund Holders: 1
Anbio Biotechnology (NASDAQ:NNNN) is one of the 13 Best German Stocks to Invest in Now. The company is engaged in the development of medical technology and the provision of in vitro diagnostics products.
It was incorporated in 2021 and is based in Frankfurt. Anbio Biotechnology (NASDAQ:NNNN) had its initial public offering in February this year on the NASDAQ Global Market, with shares trading under the ticker ‘NNNN’.
The company announced receiving $8 million in aggregate gross proceeds from the offerings, which it intends to use for sales growth, expansion of the distribution network in selected markets, research & development, and other corporate purposes.
Anbio Biotechnology (NASDAQ:NNNN)’s NASDAQ debut has garnered strong investor interest, resulting in a nearly 600% surge from its IPO price of $5. The company is also currently pivoting from pandemic tests and is expanding into oncology, cardiovascular, and infectious diseases.
However, still a major chunk of Anbio Biotechnology (NASDAQ:NNNN)’s revenue comes from COVID-related in vitro diagnostics products, which could become a significant headwind in the short run for the company with the pandemic receding.
12. Evotec SE (NASDAQ:EVO)
Number of Hedge Fund Holders: 1
Evotec SE (NASDAQ:EVO) is among the 13 Best German Stocks to Invest in Now. The company’s shares have gained over 9% in the past month, as of the close of business on July 2, amid positive recent developments.
On June 25, Evotec SE (NASDAQ:EVO) announced that it had joined the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery through multi-omics approaches. Under this initiative, the company will identify key factors that cause AKI and develop innovative and effective treatments for patients based on a molecular understanding of the disease.
Earlier in the month, Evotec SE (NASDAQ:EVO) held its annual general meeting for 2025, in which shareholders approved, with a great majority, most of the proposals put forward by the management. Around 46.45% of the registered share capital was represented in the meeting, in which CEO Dr Christian Wojczewski also discussed the company’s current situation and strategic outlook.
Investor sentiment has also been strengthened by Warburg Research’s recent coverage of the stock on June 26, in which analyst Robert-Jan van der Horst reiterated a Buy rating for Evotec SE (NASDAQ:EVO), with its price target at €11.30.
Evotec SE (NASDAQ:EVO) is a drug discovery company that focuses on developing new pharmaceutical products through the integration of breakthrough science, advanced technology, and AI-driven innovation. In May this year, it received a $2.5 million grant from the Gates Foundation to support the development of next-generation tuberculosis treatments.
11. SCHMID Group N.V. (NASDAQ:SHMD)
Number of Hedge Fund Holders: 2
SCHMID Group N.V. (NASDAQ:SHMD) is among the 13 Best German Stocks to Invest in Now. It is a global leader in providing solutions related to electronics, photovoltaics, glass, and energy systems for the high-tech industry.
Last year, SCHMID Group and Pegasus Digital Mobility Acquisition Corp announced the completion of their business combination, following which the company’s legal name became SCHMID Group N.V., with its shares trading on the Nasdaq Global Select Market under the ticker “SHMD”.
SCHMID Group N.V. (NASDAQ:SHMD) had a challenging year in 2024, largely due to the trade tensions between the United States and China. However, in an update shared on May 21, the company said the market situation is experiencing a turnaround, with incoming orders within the anticipated range.
The management has cited strong growth in the AI server segment as a key driver of the positive market trend, as it has resulted in a significant surge in volume. SCHMID Group N.V. (NASDAQ:SHMD) said that it expects the current trend to continue and intensify in 2025 and 2026, offering an encouraging outlook for the company.
CEO Christian Schmid shared the following remarks about the market:
“The current market signals clearly show that our strategic realignment is bearing fruit. The situation is visibly stabilizing – and we are seizing the opportunities provided by technological advancements, particularly in the field of artificial intelligence.”
SCHMID Group N.V. (NASDAQ:SHMD) is also exploring several financial and strategic partnership opportunities to further strengthen its market position and expand growth, which would guard against the challenges emanating from the tariff wars in the medium to long run.
10. CureVac N.V. (NASDAQ:CVAC)
Number of Hedge Fund Holders: 3
CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained nearly 16% over the past month, with a major surge following the June 12 announcement that the company had agreed to be acquired by BioNTech.
The all-stock transaction is set to bring together two complementary German companies and build on BioNTech’s impressive track record and strong position in the global mRNA industry. Under the agreement, each CureVac N.V. (NASDAQ:CVAC) share will be exchanged for $5.46 in BioNTech ADSs, resulting in an aggregate equity value of approximately $1.25 billion.
The deal represents a 55% premium for CureVac N.V. (NASDAQ:CVAC) shareholders over the three-month average share price. Upon closing, they are also expected to have a stake of between 4% and 6% in BioNTech.
Dr. Alexander Zehnder, CEO of CureVac N.V. (NASDAQ:CVAC) stated the following on the development:
“To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a disruptive technology to develop transformative therapies with greater scale and speed. For more than two decades, both companies have operated with related ambitions, often tackling challenges from different angles. This transaction aims at combining complementary scientific capabilities, proprietary technologies, and manufacturing expertise in the mRNA field under one roof.”
The transaction, which is expected to close this year, was unanimously approved by the management and supervisory boards of both companies. The German government, which held a 13% stake in CureVac N.V. (NASDAQ:CVAC) has also welcomed the deal.
9. trivago N.V. (NASDAQ:TRVG)
Number of Hedge Fund Holders: 6
trivago N.V. (NASDAQ:TRVG) is among the 13 Best German Stocks to Invest in Now. The stock has had stellar returns of 64% year-to-date, driven primarily by robust revenue growth and successful brand marketing investments.
The German company reported a 22% YOY revenue increase for the first quarter of fiscal year 2025, with strong growth registered across all three reporting segments. trivago N.V. (NASDAQ:TRVG)’s net loss and adjusted EBITDA loss also declined by 7% and 29%, respectively, during the quarter compared to the prior year.
Following the better-than-anticipated results in Q1 and an encouraging beginning to the second quarter, trivago N.V. (NASDAQ:TRVG) on April 30 raised its full-year revenue outlook to mid-teens percent year-over-year growth, along with positive Adjusted EBITDA.
trivago N.V. (NASDAQ:TRVG) is also seeing impressive returns from its strategic brand marketing investments, which are helping to increase brand awareness. The partnership with soccer coach Jürgen Klopp, along with localized marketing campaigns in Brazil and Japan, has performed well and has driven brand revenue growth across all segments.
8. Jumia Technologies AG (NYSE:JMIA)
Number of Hedge Fund Holders: 8
Jumia Technologies AG (NYSE:JMIA) is among the 13 Best German Stocks to Invest in Now. The e-commerce firm has drawn takeover interest from telecommunications company Axian Telecom, Bloomberg reported on July 1.
Mauritius-based Axian raised $600 million last month to refinance its debt and help fund a potential takeover of Jumia Technologies AG (NYSE:JMIA), said sources close to the matter. They also added that the deliberations were private and no decisions have been made yet.
Jumia Technologies AG (NYSE:JMIA) is the largest e-commerce company in Africa, with a market cap of $543 million. If the deal goes through, it is likely to help both firms expand across the continent, said the sources. Axian has been increasing its stake in Jumia, and held 8% of its shares, as of May this year.
Representatives from both companies have declined to comment on Bloomberg’s report. Shares of Jumia Technologies AG (NYSE:JMIA)’s American depositary receipts have surged by over 20% this week.
7. InflaRx N.V. (NASDAQ:IFRX)
Number of Hedge Fund Holders: 11
InflaRx N.V. (NASDAQ:IFRX) is among the 13 Best German Stocks to Invest in Now, based on hedge fund sentiment. However, the stock has plunged by 67% year-to-date, with a significant slump over the past month, following the company’s announcement on May 28 to halt its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) due to futility.
The clinical-stage biopharmaceutical company said that it decided on the recommendation of the Independent Data Monitoring Committee (IDMC), based on the data analysis of the first 30 patients in the study.
Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx N.V. (NASDAQ:IFRX) stated the following on the decision:
“We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this pioneering study targeting a significant unmet need. While the outcome is not what we had hoped it would be, InflaRx remains committed to its goal of developing new therapies for underserved patients with chronic immune-dermatological conditions, including with our oral inhibitor of C5aR, INF904, with data expected this summer.”
InflaRx N.V. (NASDAQ:IFRX) has discontinued further development of vilobelimab in PG. Instead, it will prioritize its resources on the Phase 2a trial of INF904 to treat hidradenitis suppurativa and chronic spontaneous urticaria.
6. Fresenius Medical Care AG (NYSE:FMS)
Number of Hedge Fund Holders: 11
Fresenius Medical Care AG (NYSE:FMS) is one of the 13 Best German Stocks to Invest in Now. On July 3, the company announced it had partnered with Mexico’s Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to offer High-Volume Hemodiafiltration in seven out of ten centers in the country.
The collaboration aims to build a pilot program that provides patients from low-income groups without medical coverage with access to hemodialysis therapies. Edgar Robles, Managing Director of Care Enablement Commercial Operation at Fresenius Medical Care AG (NYSE:FMS) Mexico, stated the following:
“The groundbreaking pilot program, with its mission to provide chronic kidney disease patients with access to high-quality treatments that were previously out of their reach, represents an important advancement in CKD in Mexico.”
Fresenius Medical Care AG (NYSE:FMS) and CCINSHAE have signed a two-year agreement to facilitate the installation of Fresenius Medical Care 5008S CorDiax systems at selected renal treatment centers in Mexico City and its metropolitan areas.
5. Atai Life Sciences N.V. (NASDAQ:ATAI)
Number of Hedge Fund Holders: 14
Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the 13 Best German Stocks to Invest in Now. On July 2, analysts at Canaccord Genuity lifted the stock’s price target from $11 to $12, while maintaining a Buy rating for its shares.
The adjustment followed the joint announcement by Atai Life Sciences N.V. (NASDAQ:ATAI) and Beckley Psytech Limited of encouraging results from the Phase 2b clinical trial evaluating the efficacy of a single dose of BPL-003 in patients with treatment-resistant depression (TRD).
Canaccord noted the potential commercial advantage BPL-003 could enjoy after the results stated the average time to meet readiness for discharge criteria was under two hours post-dose. The analysts added that Atai Life Sciences N.V. (NASDAQ:ATAI) remains “significantly undervalued relative to the sizes of the opportunities in the mental health indications it is targeting.”
Atai Life Sciences N.V. (NASDAQ:ATAI) and Beckley Psytech Limited plan on engaging the U.S. FDA and other agencies regarding Phase 3 trial design for patients in the coming months.
Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of mental health treatments.
4. Deutsche Bank Aktiengesellschaft (NYSE:DB)
Number of Hedge Fund Holders: 17
Deutsche Bank Aktiengesellschaft (NYSE:DB) is among the 13 Best German Stocks to Invest in Now. The company is aiming to launch its digital assets custody service next year, reported Bloomberg this week.
The bank will use crypto exchange Bitpanda’s technology unit to build the offering, said sources familiar with the matter. Deutsche Bank Aktiengesellschaft (NYSE:DB)’s corporate bank will also continue to work with Taurus SA on the service, according to the report.
Deutsche Bank Aktiengesellschaft (NYSE:DB)’s custody project plan comes at a time when financial institutions across the world have increased focus on digital assets, following encouraging new regulations in Europe and a favorable political environment in the United States under Trump’s presidency.
Last month, Deutsche Bank Aktiengesellschaft (NYSE:DB) stated it was exploring stablecoins and different forms of tokenized deposits. According to Bloomberg, this could include issuing its token or joining an industry-wide initiative.
3. BioNTech SE (NASDAQ:BNTX)
Number of Hedge Fund Holders: 29
BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases.
On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s investigational bispecific antibody BNT327 for solid tumor types.
Under the terms of the agreement, Bristol Myers Squibb will pay BioNTech SE (NASDAQ:BNTX) up to $11.1 billion for the partnership, including $3.5 billion in unconditional payments.
The deal reflects the German company’s ambition to continue a costly, long-term focus on cancer treatments, and shows that its collaboration with Pfizer for the COVID-19 vaccine was not a singular achievement.
Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company’s research, development, and commercialization of mRNA-based cancer treatments.
2. Immatics N.V. (NASDAQ:IMTX)
Number of Hedge Fund Holders: 30
Immatics N.V. (NASDAQ:IMTX) is among the 13 Best German Stocks to Invest in Now. On May 31, the company shared results from the ongoing Phase 1b clinical trial evaluating the efficacy of IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma.
The updated data showed that the treatment is well-tolerated and demonstrated durable responses with a confirmed ORR of 56%. Cedrik Britten, M.D., Chief Medical Officer at Immatics N.V. (NASDAQ:IMTX), stated the following on the development:
“Patients with advanced melanoma post-failure of checkpoint inhibition are left to face frequent and often rapid disease progression and limited long-term survival. These individuals are in urgent need of new treatments that deliver deeper and more durable responses. We believe the data presented today emphasize the strength, durability and tangible therapeutic potential of our one-time infusion PRAME cell therapy, IMA203, in this patient population. These positive results reinforce our commitment to actively advance IMA203 through the ongoing Phase 3 SUPRAME trial to bring this PRAME therapy to the market as soon as possible.”
Immatics N.V. (NASDAQ:IMTX) focuses on the research and development of potential T cell redirecting immunotherapies for cancer treatment. While the stock is down nearly 20% year-to-date, Wall Street analysts have a one-year average price target of $14.33 per share, reflecting a 151% upside potential from its current trading level.
On May 28, Deutsche Bank initiated coverage of Immatics N.V. (NASDAQ:IMTX) with a Buy rating and announced a price target of $10, with the firm’s analysis suggesting a promising outlook for the company considering its approach to treating 2L+ Cutaneous Melanoma, especially with the IMA203.
1. SAP SE (NYSE:SAP)
Number of Hedge Fund Holders: 33
SAP SE (NYSE:SAP) is among the 13 Best German Stocks to Invest in Now. The company recently won an early round in a high-profile lawsuit filed by Celonis, a leading European startup, accusing the tech giant of allegedly monopolizing parts of the business software market.
According to Bloomberg, a San Francisco federal judge on June 30 dismissed the antitrust claims from Celonis regarding SAP SE (NYSE:SAP) restricting access to data in its enterprise software systems in a way that disadvantaged competitors and favored its own Signavio unit.
However, the judge has allowed Celonis to amend and refile the claims. A Celonis spokesperson has indicated the company would revise the claim and will add further details to strengthen its case against SAP SE (NYSE:SAP) allegedly wielding its market power.
SAP SE (NYSE:SAP) denies the allegation. Following the recent court hearing, the company reiterated that it would continue to reject the claims and defend its products and business practices.
While we acknowledge the potential of SAP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SAP and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
